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ABSTRACT Severe congenital neutropenia (Kostmann
syndrome) is characterized by profound absolute neutropenia
and a maturation arrest of marrow progenitor cells at the
promyelocyte-myelocyte stage. Marrow cells from such pa-
tients frequently display a reduced responsiveness to granulo-
cyte-colony-stimulating factor (G-CSF). G-CSF binds to and
activates a specific receptor which transduces signals critical
for the proliferation and maturation of granulocytic progenitor
cells. Here we report the identification of a somatic point
mutation in one allele of the G-CSF receptor gene in a patient
with severe congenital neutropenia. The mutation results in a
cytoplasmic truncation of the receptor. When expressed in
murine myeloid cells, the mutant receptor transduced a strong
growth signal but, in contrast to the wild-type G-CSF receptor,
was defective in maturation induction. The mutant receptor
chain may act in a dominant negative manner to block gran-
ulocytic maturation.
Severe congenital neutropenia (SCN, or Kostmann syn-
drome) was first described in 1956 (1). This disorder of
granulopoiesis is characterized by severe absolute neutrope-
nia (peripheral blood neutrophil count of <0.2 x 109/L) and
a maturation arrest ofmarrow myeloid progenitor cells at the
promyelocyte-myelocyte stage. Erythropoiesis and throm-
bopoiesis are generally normal. Patients with SCN have
frequent episodes of severe bacterial infections, usually
starting in the first month of life. Affected infants have a poor
prognosis and often succumb in the first or second decade
despite improvements in supportive care. Patients also have
an increased risk for developing acute leukemia (2). Although
an autosomal recessive pattern of inheritance was suggested
for SCN, sporadic cases have been reported as well (3-6).
The etiology of SCN remains elusive. No serum inhibitors
of marrow cell growth have been detected in patients with
SCN (5). The mononuclear cells from these patients can
produce biologically active granulocyte-colony-stimulating
factor (G-CSF) and the serum levels of G-CSF are generally
increased (7-9). However, cultured marrow cells from pa-
tients with SCN frequently display a markedly suppressed
responsiveness to G-CSF stimulation (4, 6, 9, 10). With the
clinical availability of recombinant hematopoietic growth
factors, it has been observed that most patients respond
favorably to in vivo administration of G-CSF, as evidenced
by a significant increase in circulating neutrophils and a
dramatic clinical improvement (3, 4, 9). In contrast, therapy
with granulocyte/macrophage-colony-stimulating factor
(GM-CSF) is generally ineffective in SCN. These data sug-
gest that a specific defect in G-CSF signal transduction may
exist in SCN that can be overcome by providing the patients
with pharmacologic dosages of G-CSF.
G-CSF acts primarily in the granulocytic lineage and
appears to be the major hematopoietic growth factor involved
in the regulation of in vivo production of mature neutrophils
(11). G-CSF induces the proliferation, differentiation, and
survival of granulocytic progenitor cells. The diverse effects
ofG-CSF are mediated through the interaction ofG-CSF and
a specific cell surface receptor (G-CSF-R). The human
G-CSF-R cDNA predicts an 813-aa peptide with a single
membrane-spanning domain (12, 13). Expression of the hu-
man G-CSF-R in murine hematopoietic cells resulted in
high-affinity binding sites on the cell surface and rendered the
cells responsive to G-CSF (14).
The exclusive abnormality of granulopoiesis in SCN
prompted us to investigate the G-CSF-R in these patients. We
used reverse transcription (RT)-PCR to amplify the G-CSF-R
cDNA of patients with congenital neutropenia and screened
for mutations by single-strand conformation polymorphism
(SSCP) analysis. In one patient, we identified a somatic point
mutation which results in the cytoplasmic truncation of the
G-CSF-R. Further functional characterization revealed that
the truncated G-CSF-R was unable to transduce a maturation
signal.
MATERIALS AND METHODS
Patients and Sample. Patient D, a 12-year-old boy now,
suffered from severe recurrent infections from 3 days of age
onwards. The diagnosis of SCN was established on clinical
and laboratory grounds. There was no family history of
similar disease. From age 10, the patient started treatment
with recombinant human G-CSF and showed a favorable
response with an increase of neutrophils from below detect-
able to >109/L.
Bone marrow or blood samples were obtained from patient
D after informed consent from the parents. Marrow progen-
itor cells were enriched by Ficoll-Isopaque centrifugation and
complement-mediated cytolysis of mature T cells and mono-
cytes following 30 min of incubation with optimal concen-
trations of monoclonal antibodies against CD3, CD14, and
CD15 (15). CD34+ cells were then sorted following CD34
labeling (BI3C5, Sera-Lab, Crawley Down, Sussex, U.K.). T
lymphocytes were isolated from peripheral blood by eryth-
rocyte rosetting of cells from the Ficoll-Isopaque interface.
Monocytes were recovered from the latter cell population
after plastic adherence in 6-cm Petri dishes (1 hr at 3TC), and
B lymphocytes were collected as nonadherent erythrocyte-
rosette-negative mononuclear cells. Granulocytes were ob-
tained from blood as the sedimented cell fraction after
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Ficoll-Isopaque centrifugation and further depleted of eryth-
rocytes by hypotonic lysis. Erythroid colony cells were
picked from in vitro cultures supported by erythropoietin
(Epo) and interleukin 3 (IL-3).
Clonogenic Assays and Recombinant Human Growth Fac-
tors. Colony cultures were set up essentially as described
(15). Marrow cells were plated in duplicate at 1 x 104 per ml
(CD34+ cells) or 4 X 10 per ml (Ficoll interface) in semisolid
medium containing Iscove's modified Dulbecco's medium
(IMDM), 1.1% methylcellulose, 30% fetal bovine serum,
transferrin, lecithin, sodium selenite, and 2-mercaptoethanol
with or without growth factors. Colonies were scored after 14
days ofincubation at 370C in humidified 5% CO2 atmosphere.
IL-3 (Gist Brocades, Delft, The Netherlands) was used at 3
ng/ml. GM-CSF and macrophage colony stimulating factor
(M-CSF) (Genetics Institute, Cambridge, MA) were used at
25 and 50 ng/ml. G-CSF and Epo (Amgen) were used at 10
ng/ml and 1 unit/ml, respectively.
Amplification of Genomic DNA and cDNA by PCR. Ge-
nomic DNA was isolated as described (16). Total granulocyte
RNA was extracted (17) and first-strand cDNA was synthe-
sized from 1 pg ofRNA by using avian myeloblastosis virus
reverse transcriptase (Boehringer Mannheim) and oligo(dT)
or reverse primers. Three sets of primers (Table 1) were
designed to amplify the entire coding region of the G-CSF-R
cDNA. Part of exon 17 of the G-CSF-R gene was amplified
with primers FR4 and RV3. Amplification was performed
with Vent DNA polymerase (New England Biolabs) on
1/10th of the cDNA reaction mixture or 0.5 pg of genomic
DNA for 35 cycles of 1 min at 94°C, 1.5 min at 51°C, and 2
min at 72°C in a thermal cycler (Perkin-Elmer/Cetus).
SSCP Analysis. Amplified PCR fragments were purified
(Geneclean, Bio 101) after agarose gel separation and 1/100th
of the products was subjected to second-round amplification
in the presence of [a-32P]ATP. To increase the sensitivity of
SSCP analysis, the labeled products were cleaved into frag-
ments of 50-250 bp by digestion with appropriate restriction
enzymes (three or four enzymes in each case). Samples were
then denatured by boiling for 5 min in loading buffer [95%
(vol/vol) formamide/20 mM EDTA/0.05% (wt/vol) each
bromophenol blue and xylene cyanol] and loaded on a
nondenaturing 8% polyacrylamide gel (acrylamide/methyl-
enebisacrylamide weight ratio, 49:1) containing 10% (vol/
vol) glycerol. Electrophoresis at 30W for 5-8 hr was followed
by autoradiography.
Subcloning of PCR Fragments and DNA Sequencing. After
agarose gel purification, PCR fragments were ligated to the
HincII site of pBluescript (Stratagene). Nucleotide se-
quences were determined on both strands by the dideoxy
method using the T7 sequencing kit (Pharmacia).
G-CSF-R Expression Constructs. The wild-type human
G-CSF-R cDNA (13) derived from clone pHQ3 was excised
from pBluescript and inserted into the Hpa I site of the
retroviral expression vector pLNCX (18). To reconstitute a
full-length mutant cDNA, the cloned PCR fragment obtained
from granulocytes of patient D with primers FR3 and RV3
was cut with BsrFI and Cla I, and the resultant fragment of
Table 1. Primers used for PCR amplification
Primer Sequence (5' 3') Position
FR1 TCGGAAAGGTGAAGTAACTTGTCC 111-134
RV1 TCCATGGGATCAAGACACAG 818-837
FR2 TGCAGGCAGAGAATGCGCTG 777-7%
RV2 GAAGATCTCATAGAGCTGAAAG 1657-1678
FR3 TGTGATCATCGTGACTCCCTT 1669-1689
RV3 GTAGATCTTAGTCATGGGCTTATGG 2750-2774
FR4 CCATCACCAAGCTCACAGTG 2244-2263
Underlined nucleotides indicate introduced mismatches. FR, for-
ward; RV, reverse.
499 bp was used to replace the corresponding part of the wild
type G-CSF-R cloned in pLNCX.
Cell Line and Gene Transfection. A murine myeloid cell
line, L-GM (19), was maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 10%
WEHI-3B cell conditioned medium (WEHI-CM). G-CSF-R
expression constructs were linearized by Pvu I digestion and
then introduced into L-GM cells by electroporation. After
transfection, L-GM cells were selected in culture medium
containing G418 at 0.8 mg/ml. Single G418-resistant clones
were expanded and tested for the ability to respond to human
G-CSF. For maturation induction, L-GM transfectants were
transferred to RPMI 1640 containing 10o fetal bovine serum
and recombinant human G-CSF at 10 ng/ml. Cell morphology
was examined every 2-3 days.
RESULTS
In Vitro Response to Hematopoietic Growth Factors. Colony
cultures of highly enriched progenitor cells from patient D
were used to evaluate the responsiveness to several hema-
topoietic growth factors. The numbers of erythroid, macro-
phage, and eosinophilic colonies generated from marrow
cells ofpatientD in response to Epo, IL-3, and GM-CSF were
comparable to normal controls (Table 2). However, G-CSF-
induced granulocytic colony formation was significantly im-
paired. Dose titration experiments with marrow cells recov-
ered from Ficoll-Isopaque interface without further enrich-
ment revealed that the patient's marrow cells not only
generated lower numbers of granulocytic colonies but also
required higher concentration of G-CSF for maximal colony
formation than normal marrow cells (Fig. 1). These results
showed that the response to G-CSF was exclusively impaired
in the patient.
SSCP Analysis of G-CSF-R cDNA. The entire coding region
of the G-CSF-R cDNA was amplified from total RNA ex-
tracted from granulocytes of patient D by using three sets of
primers. The resultant PCR fragments were initially sepa-
rated in agarose gel, but no differences in size were detected
between the patient's and wild-type G-CSF-R. To search for
small alterations, the PCR fragments were subjected to SSCP
analysis following digestion with various restriction en-
zymes. An abnormally migrating band, in addition to the
normally migrating one, was consistently detected when the
PCR fragment extending from nt 1669 to nt 2774 (pHQ3) was
digested with Pvu II (Fig. 2, lane 9). This fragment was then
subcloned and the same mobility shift was detected in 9 out
of 16 individual clones analyzed. An abnormally migrating
band was also detected following Dde I digestion, and by
comparing the patterns of SSCP obtained after Pvu II and
Dde I digestion, the region containing the mutation was
Table 2. In vitro response of marrow progenitor cells from
normal individuals and patient D to various hematopoietic
growth factors
Colony number
Subject(s) Growth factor G M Eo E
Normal IL-3 0 0-17 15-71 0
(n = 4) GM-CSF 0 0-36 9-75 0
G-CSF 44-269 0-35 0 0
Combination* 107-450 18-83 23-61 107-450
Patient D IL-3 0 12 37 0
GM-CSF 0 7 22 0
G-CSF 7 17 0 0
Combination* 78 35 58 108
Numbers indicate colonies per 104 CD34+ cells. G, granulocytic;
M, macrophage; Eo, eosinophilic; E, erythroid.
*IL-3, GM-CSF, G-CSF, and Epo.
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FIG. 1. In vitro response to G-CSF of marrow cells from patient
D and normal individuals. A reduced sensitivity ofmarrow cells from
patient D (e) to G-CSF stimulation as compared with the marrow
cells from 3 healthy donors (o, o, *) was apparent, as indicated by
the reduced colony numbers and the much greater concentration of
G-CSF required for maximal colony formation. The results obtained
with marrow cells recovered after Ficoll-Isopaque separation are
shown. Cells were cultured at 4 x 104 per ml and colonies were
counted after 14 days of incubation.
narrowed down to nt 2311-2429. No other mutations in the
coding region of the G-CSF-R sequence were identified in
patient D or in five other patients with congenital neutropenia
and two patients with acquired idiopathic neutropenia (Fig.
2).
Identification of a Point Mutation. Five independent clones
were sequenced and a C -- T transition at nt 2384 (pHQ3) was
identified in three clones displaying the variant SSCP pat-
terns (Fig. 3). The mutation was not present in two other
clones displaying the normal SSCP pattern. Direct sequenc-
ing of PCR products amplified from genomic DNA of the
patient's granulocytes confirmed the presence of both the
normal and the mutant allele (data not shown). The mutation
changes the CAG glutamine codon to aTAG stop codon at aa
716 (Fig. 3). Thus, one of the patient alleles is predicted to
code for a truncated G-CSF-R lacking the C-terminal 98 aa.
Lineage Specificity of the Mutation. To investigate whether
the mutation was inherited or represented a de novo germline
or somatic event, a fragment of 530 bp covering the mutation
site was amplified from genomic DNA prepared from various
cellular sources of patient D and from blood mononuclear
cells of the parents. After Pvu II digestion, the amplified
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FIG. 3. Identification ofa point mutation in G-CSF-R cDNA. (A)
Partial nucleotide sequences of normal and mutant G-CSF-R cDNA.
PCR fragment amplified with primers FR3 and RV3 (nt 1669-2774)
was subcloned into the HincII site of pBluescript SK vector by
blunt-end ligation. Nucleotide sequences of five independent clones
were determined by DNA sequencing. Shown is a portion of the
nucleotide sequences spanning the point mutation (C to T) as
indicated by the arrow. The mutation was confirmed in two other
clones displaying the variant SSCP. The restriction site for Bfa I
created by the mutation is also indicated. (B) Structure of wild-type
and mutant G-CSF-Rs. Boxes 1-3, regions conserved in certain
members of the cytokine receptor family; TM, transmembrane
domain.
fragment was subjected to SSCP analysis. In two indepen-
dent experiments the mutation was readily detected in pa-
tient's granulocytes (Fig. 4, lane 2), but not in monocytes,
erythroid colony cells, T and B lymphocytes, and skin
fibroblasts of patient D (lanes 3-7). DNA isolated from
mononuclear cells of the parents manifested a normal SSCP
pattern (lanes 8 and 9). Since the C -+ T transition creates an
additional Bfa I site (CCAG CTAG; Fig. 3), we performed
2 5
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FIG. 2. Screening for mutations in the G-CSF-R gene by PCR-
SSCP analysis. The fiagment extending from nt 1669 to nt 2774 was
amplified from wild-type cDNA (pHQ3, lane 2) and reverse-
transcribed cDNA from mRNA extracted from six pediatric patients
with congenital neutropenia (lanes 3-6, 8, and 9) and two adult
patients with chronic idiopathic neutropenia (lanes 7 and 10). Part of
the autoradiograph of the SSCP gel obtained after Pvu II digestion is
shown. Position of double-strand DNA is shown in lane 1. An
abnormally migrating band was seen in lane 9 (arrow).
-
FIG. 4. Detection of the point mutation in genomic DNA from
various cell populations by PCR-SSCP analysis. Part of exon 17 of
the G-CSF-R gene that contains the mutation was amplified as
described in Materials and Methods. PCR products were digested
with Pvu II before SSCP analysis. The same abnormally migrating
band as that shown in Fig. 2 was observed in DNA isolated from
patient granulocytes (lane 2), but not in DNA from monocytes,
erythroid colony cells, T lymphocytes, B lymphocytes, and fibro-
blasts ofthe patient (lanes 3-7). DNA isolated from the mononuclear
cells of the patient's father and mother exhibits a normal SSCP
pattern (lanes 8 and 9). Lane 1 shows the SSCP pattern of wild-type
cDNA.
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Bfa I digestion of PCR products to confirm the findings and
comparable results were obtained (data not shown).
Functional Characterization of the Truncated G-CSF-R. To
show that the truncated receptor is functionally defective, the
mutant and wild-type G-CSF-R cDNAs were subcloned in
the mammalian expression vector pLNCX (18) and then
introduced into murine L-GM cells, an IL-3- and GM-CSF-
dependent myeloid cell line lacking endogenous G-CSF-R
(19). Parental L-GM cells did not show any response to
G-CSF and exhibited an immature phenotype when main-
tained in IL-3-containing medium (Fig. SA). The forced
expression of either the wild-type or the mutant receptor
rendered these cells responsive to human G-CSF. L-GM cells
expressing the wild-type G-CSF-R responded poorly to
G-CSF and lost viability gradually in G-CSF-containing me-
dium, a process which was accompanied by terminal matu-
ration of the cells toward neutrophilic granulocytes. Mor-
phological examination of the cells revealed that almost all
cells were at the end stage of granulocytic maturation after 9
days of G-CSF treatment (Fig. SB). In contrast, L-GM cells
expressing the truncated G-CSF-R continuously proliferated
in G-CSF-containing medium and did not show evidence of
terminal granulocytic maturation (Fig. SC).
DISCUSSION
SCN is a rare pediatric disorder and to date about 120 cases
have been reported (2). On the basis of the reduced in vitro
response of marrow progenitor cells to G-CSF, increased
serum levels of G-CSF, and differential therapeutic effects of
G-CSF and GM-CSF in these patients, a perturbed G-CSF
signal transduction has been suggested. Normal or increased
numbers of G-CSF-Rs are expressed on the neutrophils of
SCN patients, with affinities comparable to those on normal
neutrophils, suggesting that the aberrant response to G-CSF
in SCN is not due to alterations in G-CSF-R expression (20).
However, mutations, particularly in the cytoplasmic domain
of G-CSF-R, that affect only G-CSF signal transduction
cannot be excluded. Rauprich et al. (21) have demonstrated
that an intracellular protein of =160 kDa is spontaneously
phosphorylated in neutrophils from patients with SCN, but
not in normal neutrophils. Neutrophils from patients with
SCN display an abnormal response to fMet-Leu-Phe, with
decreased superoxide anion production and impaired mobi-
lization of cytosolic calcium (22-24). Nevertheless, the exact
nature of molecular defects in SCN has remained unknown.
We describe here the identification of a point mutation in
one allele of the G-CSF-R gene in a patient with SCN which
results in the deletion of 98 aa from the C terminus of the
receptor. The mutation was predominantly present in the
granulocytic lineage, suggesting that patient D is mosaic for
the mutation. Functional analysis of the mutant receptor
revealed that the underlying defect of the truncated G-CSF-R
was its inability to transduce signals for terminal granulocytic
maturation. These observations are consistent with the clin-
ical finding that granulocytic maturation is disturbed in
patient D and with the fact that marrow cells from the patient
displayed an exclusively abnormal response to G-CSF stim-
ulation in vitro. Our data strongly imply that the expression
of the truncated receptor is the direct cause of neutropenia in
the patient.
Two lines of evidence suggest that the truncated receptor
was expressed in patient D, although direct demonstration of
the presence of the mutant protein was hampered by the fact
that anti-human G-CSF-R antibodies are not yet available.
According to SSCP analysis the transcripts of the normal and
the mutant G-CSF-R gene were present in the patient's
granulocytes (Fig. 2). Flow cytometry with biotinylated
G-CSF demonstrated that the surface levels of both the
wild-type and the truncated G-CSF-R were low but compa-
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FIG. 5. Morphological analysis of L-GM cells transfected with
the wild-type and the mutant G-CSF-R. (A) L-GM cells grown in 10%O
WEHI cell conditioned medium (as a crude source of murine IL-3)
display a phenotype of immature myeloid cells. (B) L-GM transfec-
tants of the wild-type human G-CSF-R consist of terminally mature
neutrophilic granulocytes after incubation with G-CSF for 9 days.
(C) L-GM cells expressing the truncated G-CSF-R remain morpho-
logically immature following stimulation with G-CSF. Expression of
the G-CSF-R was confirmed by Northern blot and flow cytometric
analysis using biotinylated G-CSF. Slides were stained with May-
Grunwald-Giemsa stain.
rable in L-GM cells (data not shown). These data indicate that
the mutant G-CSF-R protein is stable and can be expressed
on the cell surface. This notion may have important impli-
cations for understanding the mechanism whereby the trun-
cated receptor interferes with the normal granulopoiesis.
Oligomerization of receptor molecules is required for high-
affinity binding and subsequent signal transduction (25-29).
Thus, the truncated G-CSF-R could form a heterodimer with
Genetics: Dong et al.
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the normal receptor chain, leading to an inability of the
receptor complex to transduce signals upon G-CSF binding.
Such a dominant negative mechanism has been suggested for
other receptors as well (30-32). On the other hand, approx-
imately one-fourth of the receptors expressed on the cell
surface would still be homodimers of the normal G-CSF-R
protein, if both the normal and the truncated receptor were
expressed at the same level. Accordingly, it would be ex-
pected that the dominant negative effect could be partially
overcome by increasing the occupancy of the residual normal
G-CSF-R complex. Indeed, the patient responded favorably
to G-CSF therapy (10 ug/kg per day) with a significant
increase of peripheral blood neutrophil count.
The isolation of the truncated G-CSF-R has provided a
unique opportunity to study G-CSF signal transduction
through its receptor. The G-CSF-R belongs to the cytokine
receptor superfamily, which is characterized by common
extracellular features (33, 34). Consensus motifs, although
less strictly, have 'also been observed in the cytoplasmic
domain of some members of the family. A membrane-
proximal region containing two subdomains designated
boxes 1 and 2 is sufficient for growth signaling (35-37).
Consistent with these observations, the truncated G-CSF-R,
which retains the two subdomains, transduces a growth
signal in marine L-GM cells. The C-terminal region of the
cytoplasmic domain of the family is less conserved and
relatively little is known about its role in signal transduction.
Our data suggest that the C-terminal region of G.,CSF-R is
involved in transducing maturation-inducing signals.
Whether these observations reflect a more common mecha-
nism of signal transduction by the cytokine receptors is
unclear.
The predominant presence of the point mutation in gran-
ulocytes suggests that progenitor cells mainly committed to
the granulocytic lineage were exclusively affected. Because
committed progenitor cells are generally thought to be inca-
pable of unlimited self-renewal, the question arises as to how
neutropenia persisted in the patient. In this respect, the
results obtained with L-GM transfectants may be informa-
tive. L-GM cells expressing the wild-type G-CSF-R matured
and died in G-CSF-containing medium. In contrast, L-GM
cells transfected with the mutant receptor proliferated con-
tinuously in response to G-CSF. Therefore, it is possible that
in the patient, because of the expression of the truncated
G-CSF-R, self-renewal of committed granulocytic progenitor
cells is favored over differentiation and subsequent cell
death, which may lead to the persistence of these progenitor
cells. This would imply that, to a certain extent, the abnormal
cell population is transformed. Notably, cases of SCN that
terminated in acute leukemia have been reported (38-40). In
addition, our data indicate that G-CSF therapy in certain
cases of SCN should be carefully evaluated, because such
treatment may lead to an overstimulation of the abnormal cell
population. At least three SCN patients have developed
leukemia or myelodysplastic syndrome following G-CSF
treatment (2).
It is conceivable that SCN consists of a heterogeneous
group of disorders with variable underlying etiology. In fact,
six patients with congenital neutropenia were initially
screened with SSCP analysis but an abnormal G-CSF-R was
identified in only one patient (Fig. 2), suggesting that abnor-
malities of molecules involved in G-CSF signal transduction
downstream of the receptor could also play a role in SCN
pathogenesis. However, with more patients being examined,
mutations in other important regions of G-CSF-R may be
identified in SCN. In addition, our results also validate the
investigation of the. involve-ment of an abnormal G-CSF-q1PR in
other neutropenias as well as in leukemia. Studies of this kind
may help to elucidate the pathogenesis of some hematopoi-
etic disorders and may improve our understanding of G-CSF
signal transduction.
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